Get the Stockscreener App
15.99
2.62%
-0.43
After Hours:
15.00
-0.99
-6.19%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Axogen Inc stock is traded at $15.99, with a volume of 764.62K.
It is down -2.62% in the last 24 hours and down -0.50% over the past month.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
See More
Previous Close:
$16.42
Open:
$16.36
24h Volume:
764.62K
Relative Volume:
0.59
Market Cap:
$735.74M
Revenue:
$203.27M
Net Income/Loss:
$-4.66M
P/E Ratio:
-159.90
EPS:
-0.1
Net Cash Flow:
$3.47M
1W Performance:
-10.57%
1M Performance:
-0.50%
6M Performance:
+1.20%
1Y Performance:
+17.57%
1-Day Range:
$15.63
$16.49
1-Week Range:
$15.63
$18.04
52-Week Range:
$9.215
$21.00
Axogen Inc Stock (AXGN) Company Profile
Name
Axogen Inc
Sector
Industry
Phone
(386) 462-6817
Address
13631 PROGRESS BLVD., ALACHUA, FL
Compare AXGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXGN
Axogen Inc
|
15.99 | 755.53M | 203.27M | -4.66M | 3.47M | -0.10 |
|
ABT
Abbott Laboratories
|
132.57 | 232.02B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
95.41 | 144.14B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.60 | 141.53B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.45 | 123.78B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.94 | 44.14B | 5.69B | 1.41B | 577.90M | 6.9828 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Initiated | Lake Street | Buy |
| Jul-01-24 | Initiated | Raymond James | Outperform |
| Nov-11-22 | Resumed | Jefferies | Buy |
| May-09-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-11-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | Guggenheim | Buy |
| Jun-16-20 | Resumed | Cantor Fitzgerald | Overweight |
| May-07-20 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-02-20 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-12-19 | Initiated | Canaccord Genuity | Buy |
| Mar-02-18 | Reiterated | Lake Street | Buy |
| Jan-05-18 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-30-17 | Initiated | Jefferies | Buy |
| Nov-21-17 | Reiterated | Lake Street | Buy |
| Jul-31-17 | Initiated | Leerink Partners | Outperform |
| Jun-30-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-06-17 | Initiated | ROTH Capital | Buy |
| Nov-22-16 | Upgrade | Lake Street | Hold → Buy |
| Nov-07-16 | Reiterated | Wedbush | Outperform |
| Nov-03-16 | Downgrade | Lake Street | Buy → Hold |
| Aug-04-16 | Reiterated | Wedbush | Outperform |
| May-14-14 | Initiated | Dawson James | Buy |
| Oct-31-13 | Reiterated | Ladenburg Thalmann | Buy |
View All
Axogen Inc Stock (AXGN) Latest News
Visual analytics tools that track Axogen Inc. performance2025 Investor Takeaways & Daily Stock Trend Watchlist - newser.com
Will Axogen Inc. stock deliver strong dividend growthGlobal Markets & Real-Time Stock Entry Alerts - newser.com
Predicting Axogen Inc. trend using moving averages2025 Pullback Review & Pattern Based Trade Signal System - newser.com
Axogen, Inc. (AXGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Volume spikes in Axogen Inc. stock – what they meanLong Setup & Fast Exit/Entry Strategy Plans - newser.com
AxoGen (NASDAQ:AXGN) Stock Price Passes Above 200-Day Moving AverageHere's What Happened - MarketBeat
Real time social sentiment graph for Axogen Inc.Stock Surge & Free Safe Entry Trade Signal Reports - newser.com
Why Axogen Inc. is moving today2025 Market Outlook & Reliable Breakout Forecasts - newser.com
How sentiment analysis helps forecast Axogen Inc.Portfolio Update Report & Verified Momentum Watchlists - newser.com
Can Axogen Inc. stock weather global recessionJuly 2025 Decliners & Low Risk High Reward Ideas - newser.com
AxoGen's (AXGN) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Market reaction to Axogen Inc.’s recent newsQuarterly Growth Report & Detailed Earnings Play Alerts - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc.AXGN - WV News
Axogen, Inc. Experiences Evaluation Revision Amidst Shifting Market Dynamics and Performance Indicators - Markets Mojo
Insider Sell: Burke William P. Mr. Sells Shares of Axogen Inc (A - GuruFocus
William Mr. Burke Sells 736 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat
Axogen Stock Forms Golden Cross, Signaling Potential Bullish Breakout Ahead - Markets Mojo
William Mr. Burke Sells 14,571 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat
AxoGen (NASDAQ:AXGN) Director Sells $137,236.20 in Stock - MarketBeat
Axogen Director William P. Burke Sells Over 32,000 Shares - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages Axogen, Inc. (AXGN) Investors to Inquire about Securities Investigation - ACCESS Newswire
Can Axogen Inc. stock continue upward trendGap Down & Free AI Powered Buy and Sell Recommendations - newser.com
How to recover losses in Axogen Inc. stockJuly 2025 Earnings & Reliable Momentum Entry Alerts - newser.com
Is FDA Review Delay and Legal Scrutiny Altering the Investment Case for Axogen (AXGN)? - Sahm
A Look at Axogen (AXGN) Valuation Following FDA Avance Delay and Securities Law Probe - Yahoo Finance
AxoGen, Inc. (NASDAQ:AXGN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Axogen, Inc. (AXGN) And Encourages Stockholders to Reach Out - ACCESS Newswire
Combining price and volume data for Axogen Inc.Trend Reversal & Safe Investment Capital Preservation Plans - newser.com
HighMark Wealth Management LLC Has $1.06 Million Position in AxoGen, Inc. $AXGN - MarketBeat
Equities Analysts Issue Forecasts for AxoGen Q3 Earnings - MarketBeat
FDA Extends Review for AxoGen’s Avance Nerve Graft - MSN
Canaccord Genuity reiterates Buy rating on AxoGen stock, citing BLA approval potential - Investing.com
AxoGen (NASDAQ:AXGN) Coverage Initiated at HC Wainwright - Defense World
Canaccord Genuity maintains Buy rating on AxoGen stock amid shutdown concerns - Investing.com Nigeria
Axogen, Inc. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your Rights – AXGN - MarketScreener
AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm - The Globe and Mail
CCORF Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
AxoGen (NASDAQ:AXGN) Now Covered by HC Wainwright - MarketBeat
AxoGen stock rating reiterated as Buy by H.C. Wainwright By Investing.com - Investing.com Nigeria
AxoGen stock rating reiterated as Buy by H.C. Wainwright - Investing.com Nigeria
HC Wainwright Initiates Axogen at Buy With $25 Price Target - MarketScreener
AXGN: HC Wainwright & Co. Initiates Coverage With Buy Rating | A - GuruFocus
Axogen Inc Stock (AXGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Axogen Inc Stock (AXGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Burke William P. Mr. | Director |
Oct 03 '25 |
Sale |
18.21 |
14,571 |
265,283 |
2,293 |
| Burke William P. Mr. | Director |
Oct 03 '25 |
Sale |
18.21 |
7,600 |
138,367 |
0 |
| Burke William P. Mr. | Director |
Oct 02 '25 |
Sale |
18.01 |
7,620 |
137,200 |
16,864 |
| Burke William P. Mr. | Director |
Oct 02 '25 |
Sale |
18.01 |
2,400 |
43,224 |
7,600 |
1.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):